Tirzepatide is a dual GIP and GLP-1 receptor agonist studied in molecular pharmacology and large human trials of glycemic control and body weight.
Explore the research profileSubmit an unpaid laboratory order request for manual review. Availability and any pending amounts require confirmation.
Catalog quantities are not assay results.
GIP and GLP-1 receptor agonist
Tirzepatide, originally designated LY3298176, is a fatty-acid-modified peptide with activity at two incretin receptors. Its design combines glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 signaling in one molecule, rather than combining two separate medicines or acting as a glucagon receptor agonist.
This reference describes the published literature. Exact supplied form and chemical specifications require product-specific documentation. The studies are linked in Selected literature.
Discovery experiments demonstrated activation of both GIP and GLP-1 receptor pathways, with glucose-dependent insulin secretion and metabolic effects in animal models. Chemical modification prolonged exposure. Receptor balance and downstream effects remain experimentally important because dual activity cannot be reduced to a simple sum of two isolated signals.
The discovery program used receptor-expressing cells, mice and early human studies to link molecular activity with metabolic measurements. This translational sequence supports investigation of the dual mechanism, but does not establish equivalence between clinical formulations and independently sourced peptide materials. [1]
SURPASS-2 compared tirzepatide with a specified semaglutide regimen in adults with type 2 diabetes. It found larger glycated-hemoglobin reductions with tirzepatide under the tested conditions. Its open-label design and chosen comparator matter when interpreting the comparison. [2]
SURMOUNT-1 randomized 2,539 adults with obesity or overweight and associated complications, excluding diabetes. Tirzepatide produced greater average weight reduction than placebo. The trial also recorded tolerability and discontinuation, providing a fuller assessment than weight change alone. [3]
Study topics describe the cited models, not established benefits of this catalog material.
The cited literature connects receptor biology with controlled human evidence for two distinct outcomes: glycemic control and body-weight reduction. Gastrointestinal events were common in the trials. These results concern defined patient populations, clinical oversight and the pharmaceutical preparations studied.
A comparison against one semaglutide regimen is not a universal ranking across all formulations or clinical settings. Trial averages do not guarantee individual outcomes, and these references do not answer every long-term or disease-specific question. They do not substantiate claims about WYZ manufacturing, purity, safety or clinical-product equivalence.
Primary studies and clearly identified supporting sources. Each link opens the original record.
Discovery pharmacology and early human proof of concept; title abbreviated.
SURPASS-2 open-label comparison with a specified semaglutide regimen.
SURMOUNT-1 placebo-controlled obesity trial excluding diabetes.
Literature reviewed October 2026. This is a selected research overview, not an exhaustive systematic review. Published findings do not establish the identity, purity, sterility or suitability of any WYZ batch. For laboratory research only; not for human or veterinary use.
Final product specifications and product-specific storage instructions have not been supplied. Review the original documentation and your laboratory’s procedures before obtaining or using the material.
For qualified laboratory researchers. Not for human or veterinary use. Product information is not medical advice or a recommendation for personal use.
What to look for in a COAOther single compounds in the collection.
Metabolic Research
Retatrutide is a synthetic peptide studied for coordinated activation of three metabolic hormone receptors, with human research examining glucose regulation, appetite, body weight and liver fat.
Metabolic Research
MOTS-c is a mitochondrial-derived peptide studied in metabolic signaling and skeletal-muscle adaptation, with experimental interventions supported mainly by cell and animal evidence.
Dermal Research
GHK-Cu is a copper complex of glycyl-histidyl-lysine studied for its effects on extracellular-matrix production and remodeling in experimental tissue-repair systems.
